Ultima Genomics reported TRACERx trial data supporting a whole-genome ctDNA approach using duplex sequencing without bespoke tumor-informed assays. At AACR, Jonathan Wan of UCL and the Francis Crick Institute presented pilot cohort findings using ppmSeq, a paired plus-minus sequencing method designed for error suppression and improved recovery. The analysis used samples collected 120 days after surgery and showed concordance with earlier TRACERx data while predicting relapse-free survival over roughly eight years. Ultima said the method tracked a far larger number of mutations per patient than prior tumor-informed capture-panel approaches, enabling more refined relapse risk stratification. Following the pilot, the team plans to test ppmSeq in a larger cohort and explore tumor-agnostic signature detection, reflecting a push toward scalable MRD monitoring.